Translate

BSE-NSE Ticker

Monday, June 21, 2010

Cadila Healthcare receives phase-I clinical trial permission from DCGI

Cadila Healthcare has received phase-I clinical trial permission from the DCGI for ZYOG1, a novel GLP-1 agonist, designed and developed at the company's research centre using a unique platform technology. ZYOG1 is a novel, oral anti-diabetic molecule.

No comments:

Economic Event Calendar

Economic Calendar >> Add to your site

Best Mutual Funds

Recent Posts

Search This Blog

IPO's Calendar

Market Screener

Industry Research Reports

NSE BSE Tiker

Custom Pivot Calculator

Popular Posts

Market & MF Screener

Company Research Reports